Alexander D Sherry1, Rie von Eyben2, Neil B Newman3, Paulina Gutkin2, Ingrid Mayer4, Kathleen Horst2, A Bapsi Chakravarthy3, Marjan Rafat5. 1. Vanderbilt University School of Medicine, Nashville, Tennessee. 2. Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. 3. Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Chemical and Biomolecular Engineering, Vanderbilt University School of Engineering, Nashville, Tennessee; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, Tennessee. Electronic address: marjan.rafat@vanderbilt.edu.
Abstract
PURPOSE: Patients with triple-negative breast cancer experience high rates of recurrence after radiation, which may be facilitated by the recruitment of circulating tumor cells to proinflammatory microenvironments in the absence of lymphocytes. We hypothesized that patients with lymphopenia and elevated inflammatory hematologic markers after radiation therapy would have an increased risk of locoregional failure. METHODS AND MATERIALS: With approval, we retrospectively studied a cohort of women treated with adjuvant radiation therapy for stage II-III triple-negative breast cancer. We analyzed the relationship between post-radiation therapy neutrophil:lymphocyte ratio (NLR) and locoregional recurrence by using Cox regression. RESULTS: One-hundred thirty patients met inclusion criteria, and median follow-up time was 7.6 years. Patients with an NLR ≥3 had a higher rate of locoregional failure (P = .04) and lower overall survival (P = .04). After adjusting for stage (hazard ratio [HR], 5.5; P < .0001) and neoadjuvant chemotherapy (HR, 2.5; P = .0162), NLR was highly predictive of locoregional failure (HR, 1.4; P = .0009). NLR was also highly predictive of overall survival (HR, 1.3; P = .0007) after adjustment for stage and neoadjuvant chemotherapy. CONCLUSIONS: Innate peripheral inflammation after radiation therapy for triple-negative breast cancer in an immunocompromised setting may be a novel prognostic biomarker for locoregional recurrence, progression, and survival. This finding supports preclinical studies of post-radiation therapy inflammation-mediated tumor progression. Further studies are needed to confirm this finding and develop treatment strategies.
PURPOSE:Patients with triple-negative breast cancer experience high rates of recurrence after radiation, which may be facilitated by the recruitment of circulating tumor cells to proinflammatory microenvironments in the absence of lymphocytes. We hypothesized that patients with lymphopenia and elevated inflammatory hematologic markers after radiation therapy would have an increased risk of locoregional failure. METHODS AND MATERIALS: With approval, we retrospectively studied a cohort of women treated with adjuvant radiation therapy for stage II-III triple-negative breast cancer. We analyzed the relationship between post-radiation therapy neutrophil:lymphocyte ratio (NLR) and locoregional recurrence by using Cox regression. RESULTS: One-hundred thirty patients met inclusion criteria, and median follow-up time was 7.6 years. Patients with an NLR ≥3 had a higher rate of locoregional failure (P = .04) and lower overall survival (P = .04). After adjusting for stage (hazard ratio [HR], 5.5; P < .0001) and neoadjuvant chemotherapy (HR, 2.5; P = .0162), NLR was highly predictive of locoregional failure (HR, 1.4; P = .0009). NLR was also highly predictive of overall survival (HR, 1.3; P = .0007) after adjustment for stage and neoadjuvant chemotherapy. CONCLUSIONS: Innate peripheral inflammation after radiation therapy for triple-negative breast cancer in an immunocompromised setting may be a novel prognostic biomarker for locoregional recurrence, progression, and survival. This finding supports preclinical studies of post-radiation therapy inflammation-mediated tumor progression. Further studies are needed to confirm this finding and develop treatment strategies.
Authors: Qods Lahmar; Jiri Keirsse; Damya Laoui; Kiavash Movahedi; Eva Van Overmeire; Jo A Van Ginderachter Journal: Biochim Biophys Acta Date: 2015-07-02
Authors: J A van der Hage; C J van de Velde; J P Julien; M Tubiana-Hulin; C Vandervelden; L Duchateau Journal: J Clin Oncol Date: 2001-11-15 Impact factor: 44.544
Authors: Ioana Danciu; James D Cowan; Melissa Basford; Xiaoming Wang; Alexander Saip; Susan Osgood; Jana Shirey-Rice; Jacqueline Kirby; Paul A Harris Journal: J Biomed Inform Date: 2014-02-14 Impact factor: 6.317
Authors: Luke R G Pike; Andrew Bang; Brandon A Mahal; Allison Taylor; Monica Krishnan; Alexander Spektor; Daniel N Cagney; Ayal A Aizer; Brian M Alexander; Osama Rahma; Tracy Balboni; Patrick A Ott; F Stephen Hodi; Jonathan D Schoenfeld Journal: Int J Radiat Oncol Biol Phys Date: 2018-09-15 Impact factor: 7.038
Authors: Anosheh Afghahi; Natasha Purington; Summer S Han; Manisha Desai; Emma Pierson; Maya B Mathur; Tina Seto; Caroline A Thompson; Joseph Rigdon; Melinda L Telli; Sunil S Badve; Christina N Curtis; Robert B West; Kathleen Horst; Scarlett L Gomez; James M Ford; George W Sledge; Allison W Kurian Journal: Clin Cancer Res Date: 2018-03-26 Impact factor: 13.801
Authors: Hyeon Kang Koh; Younghee Park; Taeryool Koo; Hae Jin Park; Me Yeon Lee; Ah Ram Chang; Semie Hong; Hoonsik Bae Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Jun Su Park; Jeong Il Yu; Do Hoon Lim; Heerim Nam; Young Il Kim; Jeeyun Lee; Won Ki Kang; Se Hoon Park; Seung Tae Kim; Jung Yong Hong; Tae Sung Sohn; Jun Ho Lee; Ji Yeong An; Min Gew Choi; Jae Moon Bae Journal: Biomedicines Date: 2022-06-30